| |  Online-Ressource |
|---|
| Verfasst von: | Amarenco, Pierre [VerfasserIn]  |
|---|
| | Bogousslavsky, Julien [VerfasserIn] |
|---|
| | Callahan, Alfred S. [VerfasserIn] |
|---|
| | Goldstein, Larry [VerfasserIn] |
|---|
| | Hennerici, Michael G. [VerfasserIn] |
|---|
| | Sillsen, Henrik [VerfasserIn] |
|---|
| | Welch, Michael A. [VerfasserIn] |
|---|
| | Zivin, Justin A. [VerfasserIn] |
|---|
| Titel: | Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study |
|---|
| Verf.angabe: | the SPARCL Investigators |
|---|
| E-Jahr: | 2003 |
|---|
| Jahr: | September 19, 2003 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Prepared by the SPARCL Publications Committee for the SPARCL Investigators: Pierre Amarenco, Julien Bogousslavsky, Alfred S. Callahan, Larry Goldstein, Michael Hennerici, Henrik Sillsen, Michael A. Welch, Justin Zivin ; Gesehen am 01.06.2022 |
|---|
| Titel Quelle: | Enthalten in: Cerebrovascular diseases |
|---|
| Ort Quelle: | Basel : Karger, 1991 |
|---|
| Jahr Quelle: | 2003 |
|---|
| Band/Heft Quelle: | 16(2003), 4, Seite 389-395 |
|---|
| ISSN Quelle: | 1421-9786 |
|---|
| Abstract: | Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention. |
|---|
| DOI: | doi:10.1159/000072562 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1159/000072562 |
|---|
| | DOI: https://doi.org/10.1159/000072562 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Adult |
|---|
| | Aged |
|---|
| | Aged, 80 and over |
|---|
| | Atorvastatin |
|---|
| | Cholesterol |
|---|
| | Double-Blind Method |
|---|
| | Endpoint Determination |
|---|
| | Female |
|---|
| | Heptanoic Acids |
|---|
| | Humans |
|---|
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|---|
| | Male |
|---|
| | Middle Aged |
|---|
| | Multicenter Studies as Topic |
|---|
| | Patient Selection |
|---|
| | Prospective Studies |
|---|
| | Pyrroles |
|---|
| | Randomized Controlled Trials as Topic |
|---|
| | Research Design |
|---|
| | Secondary Prevention |
|---|
| | Stroke |
|---|
| K10plus-PPN: | 1805529285 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study / Amarenco, Pierre [VerfasserIn]; September 19, 2003 (Online-Ressource)
